TrialArthritis research & therapy2021

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).

Hideto Kameda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.